Retatrutide 10MG
Retatrutide 10MG | GIP / GLP-1 / Glucagon Receptor Agonist
The “3-G” agonist represents the leading edge of metabolic research into multi-pathway weight homeostasis.
Retatrutide is a synthetic peptide that acts as a triple agonist. It targets three critical metabolic pathways simultaneously: the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor, the Glucagon-Like Peptide-1 (GLP-1) receptor, and the Glucagon (GCG) receptor. This “triple-hit” approach is researched for its unprecedented impact on lipid metabolism, appetite suppression, and energy expenditure.
Research Benchmarks: Triple Agonism Synergy
- Maximal Weight Reduction: Studying the cumulative effect of triple signaling on adipose tissue loss.
- Hepatic Metabolic Health: Investigating the reduction of liver fat via glucagon receptor activation.
- Glycemic Control: Researching the potentiation of insulin secretion and glucose-lowering effects.
Scientific Reference Library
- 🧪 Research: Efficacy and safety of the triple agonist Retatrutide
- 🧪 Research: Pharmacology of GIP/GLP-1/Glucagon receptor tri-agonism
- 🧪 Research: Impact of Retatrutide on metabolic-associated fatty liver disease
STRICTLY FOR LABORATORY RESEARCH PURPOSES ONLY.
$101.13
